GlassScriptPhysician profile
Devin M Mckelvey
NPI 1104288638
$981.86
in general payments reported to CMS, 2019-2025
14 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.89 · 2021: $79.04 · 2022: $47.53 · 2023: $49.34 · 2024: $114 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $270.05 | 2023-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $157.06 | 2025 | Tarpeyo |
| Ardelyx, INC. | $95.30 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $73.08 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $72.23 | 2025 | Fluency Endovascular Stent Graft, Covera |
| Nxstage Medical, INC. | $58.89 | 2019 | |
| Lilly USA, LLC | $55.49 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $55.26 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $30.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $24.75 | 2025 | Velphoro |
| Novo Nordisk INC | $22.87 | 2025 | Wegovy |
| Opko Pharmaceuticals, LLC | $21.81 | 2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $18.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Mckelvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.